Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency

Rachael F. Grace(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Bertil Glader(Stanford University), F. Galactéros(Université Paris-Est Créteil), Hassan M. Yaish(Primary Children's Hospital), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Sujit Sheth(Columbia University Irving Medical Center), Bruce A. Silver(Johns Hopkins Hospital), Chris Bowden(Agios Pharmaceuticals (United States)), D. Holmes Morton(Clinic for Special Children), Yaddanapudi Ravindranath(The Barbara Ann Karmanos Cancer Institute), Kevin H.M. Kuo(University Health Network), Marie-Hélène Jouvin(Agios Pharmaceuticals (United States)), Peter Hawkins(Agios Pharmaceuticals (United States)), Janet L. Kwiatkowski(Children's Hospital of Philadelphia), Ann Barbier(Agios Pharmaceuticals (United States)), Christian Rosé(Klinik und Poliklinik für Hautkrankheiten), Lei Hua(Agios Pharmaceuticals (United States)), D. Mark Layton(Imperial College Healthcare NHS Trust), Eduard J. van Beers(Utrecht University), Charles Kung(Agios Pharmaceuticals (United States)), Susan Bodie(Agios Pharmaceuticals (United States))
New England Journal of Medicine
September 4, 2019
Cited by 162


Related Papers